ライフサイエンスコーパス: multidrug-resistant tuberculosis

1 second-line therapy for patients who develop multidrug-resistant tuberculosis.

2 tuberculosis; the remaining 603 patients had multidrug-resistant tuberculosis.

3 nteresting possibilities in the treatment of multidrug-resistant tuberculosis.

4 cin, is now widely accepted for treatment of multidrug-resistant tuberculosis.

5 of second-line therapy for the treatment of multidrug-resistant tuberculosis.

6 2 percent continued to receive treatment for multidrug-resistant tuberculosis.

7 cterial agents being used clinically against multidrug-resistant tuberculosis.

8 h all-cause mortality among US patients with multidrug-resistant tuberculosis.

9 th a potential for immunotherapy in treating multidrug-resistant tuberculosis.

10 for the development of novel drugs to tackle multidrug-resistant tuberculosis.

11 ctinomycin antibiotic essential for treating multidrug-resistant tuberculosis.

12 terial, used in the treatment of adults with multidrug-resistant tuberculosis.

13 ring their life and 13 (17%) had undiagnosed multidrug-resistant tuberculosis.

14 pert MTB/RIF assay to identify patients with multidrug-resistant tuberculosis.

15 d those of the purported source patient with multidrug-resistant tuberculosis.

16 roups reflects the local risk of transmitted multidrug-resistant tuberculosis.

17 riteria for the systematic review of risk of multidrug-resistant tuberculosis.

18 shorten the duration of therapy and to treat multidrug-resistant tuberculosis.

19 addition of clofazimine in a mouse model of multidrug-resistant tuberculosis.

20 e antimycobacterial drugs currently used for multidrug-resistant tuberculosis.

21 elamanid could enhance treatment options for multidrug-resistant tuberculosis.

22 therapy for contacts of cases of infectious multidrug-resistant tuberculosis.

23 e conversion at 2 months among patients with multidrug-resistant tuberculosis.

24 ment were critical to limiting the spread of multidrug- resistant tuberculosis.

25 Of 608 patients with multidrug resistant tuberculosis, 29 (4.8%) patients had

26 Multidrug-resistant tuberculosis, a disease caused by My

27 one to estimate the setting-specific risk of multidrug-resistant tuberculosis among child cases of tu

28 The model for risk of multidrug-resistant tuberculosis among children with tub

29 ming increase in the number of patients with multidrug-resistant tuberculosis and extensively drug-re

30 focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacte

31 The increase in multidrug-resistant tuberculosis and high mortality amon

32 uenza, as well as emerging challenges (e.g., multidrug-resistant tuberculosis and pneumococcus).

33 improve treatment outcomes for patients with multidrug-resistant tuberculosis and prevent the spread

34 Diagnosis of multidrug-resistant tuberculosis and prompt initiation o

35 outcomes for extensively drug-resistant and multidrug-resistant tuberculosis and the slow progress i

36 Multidrug-resistant tuberculosis and XDR tuberculosis gr

37 ence, a 242% increase in prevalent untreated multidrug-resistant tuberculosis, and a 275% increase in

38 e tuberculosis, extrapulmonary tuberculosis, multidrug-resistant tuberculosis, and asymptomatic tuber

39 Secondary outcomes were missed tuberculosis, multidrug-resistant tuberculosis, and comorbidities with

40 luating new agents/regimens for treatment of multidrug-resistant tuberculosis; and (3) evaluating saf

41 ensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of acces

42 We evaluated the MDR-TB (multidrug-resistant tuberculosis) assay, which uses PCR-

43 Multidrug-resistant tuberculosis at treatment initiation

44 well served by licensing of new regimens for multidrug-resistant tuberculosis based on biomarker evid

45 WGS diagnosed a case of multidrug-resistant tuberculosis before routine diagnosi

46 sis burden and half of countries with a high multidrug-resistant tuberculosis burden had incorporated

47 by year, geographic region, tuberculosis or multidrug-resistant tuberculosis burden, and prison popu

48 n settings with more ongoing transmission of multidrug-resistant tuberculosis, but results were other

49 ing percentage reduction in the incidence of multidrug-resistant tuberculosis by 2024 compared with c

50 Community-based outpatient treatment of multidrug-resistant tuberculosis can yield high cure rat

51 system increased referrals from presumptive multidrug-resistant tuberculosis cases by >10-fold, with

52 mmarize, a very high proportion of pulmonary multidrug-resistant tuberculosis cases in Los Angeles Co

53 s Angeles County by comparing relatedness of multidrug-resistant tuberculosis cases using restriction

54 diagnosis was completed and discovered a new multidrug-resistant tuberculosis cluster.

55 idrug-resistant tuberculosis will be primary multidrug-resistant tuberculosis compared with only 15%

56 ovements in treatment for drug-sensitive and multidrug-resistant tuberculosis could reduce the number

57 Health Organization outcome definitions for multidrug-resistant tuberculosis, cure rates at 120 week

58 ealthcare workers with the goal of improving multidrug-resistant tuberculosis detection.

59 derscore that many cases of tuberculosis and multidrug-resistant tuberculosis disease are not being d

60 orldwide population, the global incidence of multidrug-resistant tuberculosis disease in children has

61 to estimate regional and global incidence of multidrug-resistant tuberculosis disease in children in

62 atical models predict that the future of the multidrug-resistant tuberculosis epidemic will depend on

63 en has potential to substantially lessen the multidrug-resistant tuberculosis epidemic, but this effe

64 en has potential to substantially lessen the multidrug-resistant tuberculosis epidemic, but this effe

65 rge public health and societal implications, multidrug-resistant tuberculosis has been long regarded

66 Multidrug-resistant tuberculosis has emerged as a major

67 The increasing rate of multidrug-resistant tuberculosis has led to more use of

68 ns in the primary analysis, the incidence of multidrug-resistant tuberculosis in 2024 would be 3.3 (9

69 d the results of community-based therapy for multidrug-resistant tuberculosis in a poor section of Li

70 31 studies reported the risk of multidrug-resistant tuberculosis in both children and tr

71 the regional and global annual incidence of multidrug-resistant tuberculosis in children.

72 ore proactive screening for tuberculosis and multidrug-resistant tuberculosis in inpatient settings i

73 Despite the prevalence of multidrug-resistant tuberculosis in nearly all low-incom

74 ent with individualized regimens for chronic multidrug-resistant tuberculosis in northern Lima.

75 Similar to the outbreaks of multidrug-resistant tuberculosis in the 1990s, poor infe

76 ounted for nearly one fourth of the cases of multidrug-resistant tuberculosis in the United States du

77 est number of patients with tuberculosis and multidrug-resistant tuberculosis in the world.

78 of isoniazid resistance, a 152% increase in multidrug-resistant tuberculosis incidence, a 242% incre

79 rculosis, and a 275% increase in the risk of multidrug-resistant tuberculosis infection.

80 Multidrug-resistant tuberculosis is a major global healt

81 Multidrug-resistant tuberculosis is a man-made problem.

82 Multidrug-resistant tuberculosis is an increasing health

83 Preventing transmission of multidrug-resistant tuberculosis is critical because of

84 d-resistant tuberculosis is more common than multidrug-resistant tuberculosis, it has been much less

85 ope is complicated by the high prevalence of multidrug-resistant tuberculosis, low rates of drug susc

86 Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, to

87 INTRODUCTION: Globally, multidrug resistant tuberculosis (MDR-TB) remains underd

88 Nosocomial transmission of multidrug-resistant tuberculosis (MDR TB) has been repor

89 with multidrug chemotherapy to patients with multidrug-resistant tuberculosis (MDR TB) induces measur

90 For treating multidrug-resistant tuberculosis (MDR TB), the World Hea

91 f a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospect

92 former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are though

93 ed at our institution from 1983 to 1994 with multidrug-resistant tuberculosis (MDR-TB) and evaluated

94 have great potential to limit the spread of multidrug-resistant tuberculosis (MDR-TB) and extensivel

95 It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year.

96 n (RMP) and isoniazid (INH) and in detecting multidrug-resistant tuberculosis (MDR-TB) in comparison

97 patients successfully treated for pulmonary multidrug-resistant tuberculosis (MDR-TB) in Tomsk, Russ

98 Multidrug-resistant tuberculosis (MDR-TB) is an importan

99 Multidrug-resistant tuberculosis (MDR-TB) is associated

100 infection among contacts of individuals with multidrug-resistant tuberculosis (MDR-TB) is controversi

101 Less than 30% of multidrug-resistant tuberculosis (MDR-TB) patients are c

102 antibiotics recommended for the treatment of multidrug-resistant tuberculosis (MDR-TB) patients.

103 Multidrug-resistant tuberculosis (MDR-TB) poses a seriou

104 Multidrug-resistant tuberculosis (MDR-TB) presents an in

105 To realize the most benefit from multidrug-resistant tuberculosis (MDR-TB) screening, all

106 Multidrug-resistant tuberculosis (MDR-TB), caused by dru

107 ay, a diagnostic test for rapid detection of multidrug-resistant tuberculosis (MDR-TB), in Rwanda.

108 Tuberculosis, including multidrug-resistant tuberculosis (MDR-TB), is a major gl

109 ip-based VerePLEX Biosystem for detection of multidrug-resistant tuberculosis (MDR-TB), obtaining a d

110 All patients had multidrug-resistant tuberculosis (MDR-TB).

111 riptions of drug resistance in patients with multidrug-resistant tuberculosis (MDR-TB).

112 l impact of rapid diagnostic tests to detect multidrug-resistant tuberculosis (MDR-TB).

113 nes are the core drugs for the management of multidrug-resistant tuberculosis (MDR-TB).

114 that nonadherence is the proximate cause of multidrug-resistant tuberculosis (MDR-tuberculosis) emer

115 e the etiology of "hotspots" of concentrated multidrug-resistant tuberculosis (MDR-tuberculosis) risk

116 Multidrug-resistant tuberculosis (MDRTB) has emerged as

117 at which most countries with high burdens of multidrug-resistant tuberculosis (MDRTB) have scaled up

118 The fitness of multidrug-resistant tuberculosis (MDRTB) relative to dru

119 ly been used to predict the future burden of multidrug-resistant tuberculosis (MDRTB).

120 s that have >5% prevalence (or incidence) of multidrug-resistant tuberculosis (MDRTB).

121 health care worker, all of whom had AIDS) of multidrug-resistant tuberculosis occurred in a hospital

122 suicide gene especially for the treatment of multidrug-resistant tuberculosis once a delivery strateg

123 d be especially beneficial for patients with multidrug-resistant tuberculosis or extensively drug-res

124 of net culture conversion were no history of multidrug-resistant tuberculosis (p=0.0007) and use of c

125 , as compared with 400 patients (66.3%) with multidrug-resistant tuberculosis (P=0.36).

126 he public sector contributed 87% of acquired multidrug-resistant tuberculosis, related to irregular a

127 multiplied the setting-specific estimates of multidrug-resistant tuberculosis risk and tuberculosis i

128 ntly shortened regimens for the treatment of multidrug-resistant tuberculosis (TB).

129 ay, 2016, WHO endorsed a 9 month regimen for multidrug-resistant tuberculosis that is cheaper and pot

130 Multidrug-resistant tuberculosis threatens to reverse re

131 cal agents used to halt the progression from multidrug-resistant tuberculosis to extensively resistan

132 human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, a

133 tients with newly diagnosed, smear-positive, multidrug-resistant tuberculosis to receive either 400 m

134 each of confirmed tuberculosis and suspected multidrug-resistant tuberculosis) to a randomly allocate

135 rld Health Organization category 5 drugs for multidrug-resistant tuberculosis using a 7H9 broth micro

136 CWs in 3 district hospitals with specialized multidrug-resistant tuberculosis wards in KwaZulu-Natal,

137 identified that the setting-specific risk of multidrug-resistant tuberculosis was nearly identical in

138 00, began to increase and focal outbreaks of multidrug-resistant tuberculosis were reported.

139 d sputum-culture conversion in patients with multidrug-resistant tuberculosis, when added to a prefer

140 rospective cohort study of 608 patients with multidrug resistant tuberculosis who had treatment in ci

141 By 2032, an estimated 85% of multidrug-resistant tuberculosis will be primary multidr

142 We previously treated patients who had multidrug-resistant tuberculosis with recombinant IFN-ga

143 es in 205 patients treated at our center for multidrug-resistant tuberculosis, with strains resistant